The combination of antagonists of LHRH with antagonists of GHRH improves inhibition of androgen sensitive MDA-PCa-2b and LuCaP-35 prostate cancers (Q40108372)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	The combination of antagonists of LHRH with antagonists of GHRH improves inhibition of androgen sensitive MDA-PCa-2b and LuCaP-35 prostate cancers	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

The combination of antagonists of LHRH with antagonists of GHRH improves inhibition of androgen sensitive MDA-PCa-2b and LuCaP-35 prostate cancers (English)

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

prostate cancer

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

6

object named as

Alexandre Havt

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

9

object named as

Gabor Halmos

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Celia A Kanashiro

7

object named as

Celia A Kanashiro

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Anton Stangelberger

1

object named as

Anton Stangelberger

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

author name string

Marta Zarandi

3

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Elmar Heinrich

4

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Kate Groot

5

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Jozsef L Varga

8

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 September 2007

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

67

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

1339-1353

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Inhibition of in vivo proliferation of androgen-independent prostate cancers by an antagonist of growth hormone-releasing hormone

1 reference

https://api.crossref.org/works/10.1002%2FPROS.20605

21 January 2018

Effects of LHRH-analogues on mitogenic signal transduction in cancer cells

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20605

Increased activity of antagonists of growth hormone-releasing hormone substituted at positions 8, 9, and 10.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20605

Expression of a splice variant of the receptor for GHRH in 3T3 fibroblasts activates cell proliferation responses to GHRH analogs

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20605

Consequences of angiogenesis for tumor progression, metastasis and cancer therapy.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20605

Expression of growth hormone-releasing hormone and its receptor splice variants in human prostate cancer.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20605

Antagonistic Analogs of Growth Hormone-releasing Hormone: New Potential Antitumor Agents

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20605

Luteinizing hormone-releasing hormone (LH-RH) antagonist Cetrorelix inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of IGF-II in tumors

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20605

Luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20605

Peptide analogs in the therapy of prostate cancer.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20605

Luteinizing hormone-releasing hormone antagonist cetrorelix as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invasion of spinal cord

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20605

Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20605

Antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide inhibit tumor proliferation by different mechanisms: evidence from in vitro studies on human prostatic and pancreatic cancers

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20605

Dysregulated expression of growth factors and their receptors in the development of prostate cancer

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20605

Potentiation of the inhibitory effect of growth hormone-releasing hormone antagonists on PC-3 human prostate cancer by bombesin antagonists indicative of interference with both IGF and EGF pathways

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20605

Regulation of prostate-specific antigen (PSA) gene expression and release in LNCaP prostate cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20605

The LHRH antagonist cetrorelix: a review

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20605

Inhibition of proliferation of PC-3 human prostate cancer by antagonists of growth hormone-releasing hormone: lack of correlation with the levels of serum IGF-I and expression of tumoral IGF-II and vascular endothelial growth factor

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20605

Antagonists of growth hormone-releasing hormone (GH-RH) enhance tumour growth inhibition induced by androgen deprivation in human MDA-Pca-2b prostate cancers

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20605

Regulation of vascular endothelial growth factor expression by insulin-like growth factor I.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20605

The expression of the pituitary growth hormone-releasing hormone receptor and its splice variants in normal and neoplastic human tissues

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20605

Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20605

Inhibition of human androgen-independent PC-3 and DU-145 prostate cancers by antagonists of bombesin and growth hormone releasing hormone is linked to PKC, MAPK and c-jun intracellular signalling

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20605

Responses to the antagonistic analog of LH-RH (SB-75, Cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20605

New advances on prostate carcinogenesis and therapies: involvement of EGF-EGFR transduction system

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20605

Growth inhibition of experimental pancreatic cancers and sustained reduction in epidermal growth factor receptors during therapy with hormonal peptide analogs

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20605

Expression of growth hormone-releasing hormone (GHRH) and splice variants of GHRH receptors in human experimental prostate cancers

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20605

The development of androgen-independent prostate cancer

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20605

Isolation and sequencing of cDNAs for splice variants of growth hormone-releasing hormone receptors from human cancers.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20605

Growth hormone-releasing hormone antagonist MZ-5-156 inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of insulin-like growth factor II in tumors

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20605

Human renal cell carcinoma expresses distinct binding sites for growth hormone-releasing hormone

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20605

Antagonists of growth hormone-releasing hormone in oncology

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20605

Effects of epidermal growth factor and analogues of luteinizing hormone-releasing hormone and somatostatin on phosphorylation and dephosphorylation of tyrosine residues of specific protein substrates in various tumors

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20605

Hypothalamic hormones and cancer

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20605

High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20605

New antagonists of LHRH. II. Inhibition and potentiation of LHRH by closely related analogues.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20605

Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20605

Vascular endothelial growth factor

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20605

LuCaP 35: A new model of prostate cancer progression to androgen independence

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20605

Comparison of mechanisms of action of luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix and LHRH agonist triptorelin on the gene expression of pituitary LHRH receptors in rats

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20605

Androgen-independent growth is induced by neuropeptides in human prostate cancer cell lines

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20605

Reduction in receptors for bombesin and epidermal growth factor in xenografts of human small-cell lung cancer after treatment with bombesin antagonist RC-3095.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20605

Luteinizing hormone-releasing hormone analogs: their impact on the control of tumorigenesis

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20605

A potential autocrine pathway for growth hormone releasing hormone (GHRH) and its receptor in human prostate cancer cell lines.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20605

Inhibition of in vivo proliferation of MDA-PCa-2b human prostate cancer by a targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20605

GH-RH antagonist (MZ-4-71) inhibits VEGF secretion and proliferation of murine endothelial cells

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20605

Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20605

Early events elicited by bombesin and structurally related peptides in quiescent Swiss 3T3 cells. I. Activation of protein kinase C and inhibition of epidermal growth factor binding

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20605

Identifiers

10.1002/PROS.20605

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40108372&oldid=2119264107"